{"algorithm_version": "v0.6.0", "applied_rules": {"base_min_final_score": 68.0, "min_bullish_analyses": 2, "min_confidence": 0.62, "min_final_score": 70.0, "min_liquidity_avg_volume": 750000, "regime": "mixed", "regime_score_delta": 2.0}, "benchmark": "SPY", "catalysts": ["On October 8, 2026, AbbVie reported positive Phase 2 APEX Part B results for investigational drug zumilokibart in moderate-to-severe atopic dermatitis and said it plans to advance the program into Phase 3. The study included 346 adults, and the mid-dose regimen improved skin clearance and itching versus placebo.", "On October 7, 2026, Scotiabank maintained an outperform rating and raised its price target from $280 to $320.", "The FDA granted two Breakthrough Therapy Designations for other AbbVie drugs.", "Positive Phase 2 results for zumilokibart in a skin condition affecting millions, with plans to move to a larger Phase 3 trial, signal a growing drug pipeline.", "Two major Wall Street banks raised their price targets this week — Scotiabank to $320 and Morgan Stanley to $310 — showing strong analyst confidence."], "company_name": "AbbVie", "conviction": "high", "data_quality": 0.865, "date": "2026-10-08", "favorable_models_count": 3, "final_confidence": 0.7560299278217089, "final_score": 75.114, "generated_at": "2026-10-08T07:30:00.005470-04:00", "horizon": "intraday", "models_answered": 3, "models_asked": 3, "quantitative_score": 52.16, "reason": null, "regulatory_warning": "This is automated, general-audience analysis published for informational purposes only. It is not a personal recommendation, not a promise of performance, and not an invitation to buy or sell any financial instrument. Every investment can lose value, and past results do not predict future ones.", "risks": ["AbbVie lowered its 2026 adjusted EPS outlook to $13.76-$13.96 and cited approximately $216 million of acquired in-process research and development and milestone expenses.", "The stock is near a 52-week high after a strong rally, and its RSI of 66.7 indicates potentially crowded short-term momentum; profit-taking could limit gains.", "The stock has already risen sharply in recent days, which could lead to profit-taking.", "No fresh earnings or financial updates are expected in the next session.", "The stock is up over 8% in the past month and RSI is near 67, meaning much of the good news may already be priced in and profit-taking could follow."], "shortfalls": [], "status": "signal", "summary": "The most likely next-session drivers are the positive zumilokibart Phase 2 results and recent FDA Breakthrough Therapy Designations, reinforced by two bullish analyst price-target increases. These catalysts support a bullish bias, although the recent rally, elevated valuation, and reduced earnings guidance create a meaningful risk of profit-taking or a muted reaction.", "ticker": "ABBV", "timezone": "Europe/Zurich", "watchlist": []}